Churg-Strauss Syndrome: Vasculitis and Eosinophilic Infiltration in Systemic
Disease
As a rare multi-system vasculitic disorder associated with asthma and peripheral blood
eosinophilia, Churg-Strauss syndrome (CSS) highlights complex immune interactions
underlying chronic inflammation. Named for the pathologists describing its pulmonary
pathology in 1951, CSS predominantly afflicts the lungs, heart and nerves yet remains poorly
understood. While glucocorticoids induce remission, relapses demand judicious
immunosuppression. Molecular mechanisms continue elucidating pathogenic eosinophilia,
elucidating new therapeutic angles. This review describes CSS clinical spectrum,
histopathology, criteria for diagnosis and the evolving immunological backdrop against
which treatment continues optimization.
Clinical Presentations
CSS involves multiple organs through variable symptoms constituting four distinct phases:
- Prodromal Asthma: Persistent allergic rhinitis, asthma diagnosed ≥6
months prior onset dominates here.
- Eosinophilic Phase: Marked blood/tissue eosinophilia with pulmonary infiltrates and
cardiomyopathy potentially lethal if untreated.
- Vasculitic Phase: Mononeuritis multiplex, alveolar hemorrhage, glomerulonephritis from
small/medium vessel necrotizing angiitis arise.
- Refractory Phase: Rare untreated patients display granulomatous involvement of lungs,
heart, kidney with fibrosis complicating long-term outcomes.
Manifestations arise from circulating and tissue-infiltrating eosinophils causing endothelial
damage and ischemic tissue injury vis complement activation, releasing toxic granule
proteins and reactive oxygen species.
Histopathology
Biopsies variably display:
- Pulmonary: Eosinophilic pneumonia with interstitial/intra-alveolar infiltrates and
eosinophilic abscesses.
- Peripheral Nerve: Mononuclear perineuritis prominently involving vasculitic nerves.
- Myocardium: Epicardial, endocardial eosinophilic infiltrates with fibrotic remodeling of
myocardial architecture over time.
- Kidney: Focal necrotizing glomerulonephritis with extracapillary proliferation and crescent
formation.
Eosinophil-rich inflammatory foci intermixed with necrotizing vascular lesions propagate
multi-organ injury here.
Diagnostic Criteria
American College of Rheumatology consensus diagnosis requires four or more items
including:
- Asthma
- Eosinophilia >10% on differential
- Mononeuropathy (including multiplex) or polyneuropathy
- Non-fixed pulmonary infiltrates on radiography
- Paranasal sinus abnormality
- Biopsy demonstrating blood vessel eosinophilic infiltrates
Presence of at least two items confers 90% specificity while histology most reliably
distinguishes from hypereosinophilic syndromes lacking angiitis.
Immunopathogenesis
Though etiology remains unclear, leading hypotheses implicate:
- Genetic predisposition conveyed by HLA-DRB1*04 alleles and dysregulated T cell subsets
propagating Type 2 T-helper cell responses.
- Autoimmunity directed against self-antigens expressed on lung basement membranes
potentiating pathological eosinophilia.
- Aberrant signalling through interleukin-5, eotaxin and other eosinophilopoietic chemokines
elevating numbers/activation states.
- Eosinophil adhesion/recruitment factors directing migratory patterns towards tissues
releasing damage mediators.
- Complement activation downstream releasing C5a anaphylatoxin promoting angiogenesis
and endothelial damage.
Unraveling these pathogenic pathways informs targeted therapeutic approaches.
Treatment Strategies
In CSS, immunosuppression aims at disease control in remission induction then maintenance
phases:
- Induction reverses clinical manifestations/eosinophilia with pulsed intravenous
methylprednisolone then oral prednisone over months.
- Cytotoxic immunoablation utilizes cyclophosphamide pulsing to accelerate remission
attainment alongside glucocorticoids.
- Maintenance employs less toxic therapies minimizing relapses/complications including
azathioprine, methotrexate or mycophenolate mofetil.
- Refractory/relapsing disease warrants anti-IL5 monoclonal antibodies mepolizumab or
benralizumab depleting pathogenic eosinophils directly.
- Plasmapheresis rapidly clears autoantibodies/complement components during severe
alveolar hemorrhage or myocarditis crises.
Newer targeted molecules inhibiting specific T-cell subsets, chemokines or complement
pathways present promising adjuncts.
Challenges and Unresolved Questions
With survivorship improved, priorities emerge addressing:
- Defining predictive biomarkers guiding individualized induction/maintenance durations
limiting cumulative toxicity.
- Addressing cardiac remodeling preventing dilated cardiomyopathy contributing to long-
term mortality.
- Optimizing neuroprotective strategies halting small fiber neuropathy progression impairing
quality of life.
- Clarifying whether hypereosinophilia denotes pre-staging or phenotypic variant from
angiitis-associated CSS.
- Identifying environmental/infectious triggers breaking tolerance specifically in atopic
individuals.
- Determining whether antigen-specific immune deviations perpetuate relapsing cycles
amenable to tolerance induction.
Ongoing mechanistic studies addressing these uncertainties will translate to personalized
precision therapy optimizing outcomes.
Concluding Remarks
As an organ-damaging eosinophil-associated vasculitis, CSS showcases immunology's
complexity regulating inflammation. Considerable progress defined diagnostic criteria,
induced safer remissions yet preventing relapses/complications demands further tailored
therapies. Multi-omic studies discerning pathogenic leukocyte, cytokine and autoantibody
networks across subphenotypes will guide stratification into minimalistic targeted regimens.
Leveraging genetic risk loci may preemptively interrupt disease cascades before irreversible
injury occurs. Overall, elucidating CSS's molecular underpinnings holds promise refining
precision management for an enigmatic though medically actionable syndrome.
As a rare multi-system vasculitic disorder associated with asthma and peripheral blood
eosinophilia, Churg-Strauss syndrome (CSS) highlights complex immune interactions
underlying chronic inflammation. Named for the pathologists describing its pulmonary
pathology in 1951, CSS predominantly afflicts the lungs, heart and nerves yet remains poorly
understood. While glucocorticoids induce remission, relapses demand judicious
immunosuppression. Molecular mechanisms continue elucidating pathogenic eosinophilia,
elucidating new therapeutic angles. This review describes CSS clinical spectrum,
histopathology, criteria for diagnosis and the evolving immunological backdrop against
which treatment continues optimization.
Clinical Presentations
CSS involves multiple organs through variable symptoms constituting four distinct phases:
- Prodromal Asthma: Persistent allergic rhinitis, asthma diagnosed ≥6
months prior onset dominates here.
- Eosinophilic Phase: Marked blood/tissue eosinophilia with pulmonary infiltrates and
cardiomyopathy potentially lethal if untreated.
- Vasculitic Phase: Mononeuritis multiplex, alveolar hemorrhage, glomerulonephritis from
small/medium vessel necrotizing angiitis arise.
- Refractory Phase: Rare untreated patients display granulomatous involvement of lungs,
heart, kidney with fibrosis complicating long-term outcomes.
Manifestations arise from circulating and tissue-infiltrating eosinophils causing endothelial
damage and ischemic tissue injury vis complement activation, releasing toxic granule
proteins and reactive oxygen species.
Histopathology
Biopsies variably display:
- Pulmonary: Eosinophilic pneumonia with interstitial/intra-alveolar infiltrates and
eosinophilic abscesses.
- Peripheral Nerve: Mononuclear perineuritis prominently involving vasculitic nerves.
- Myocardium: Epicardial, endocardial eosinophilic infiltrates with fibrotic remodeling of
myocardial architecture over time.
- Kidney: Focal necrotizing glomerulonephritis with extracapillary proliferation and crescent
formation.
Eosinophil-rich inflammatory foci intermixed with necrotizing vascular lesions propagate
multi-organ injury here.
Diagnostic Criteria
American College of Rheumatology consensus diagnosis requires four or more items
including:
- Asthma
- Eosinophilia >10% on differential
- Mononeuropathy (including multiplex) or polyneuropathy
- Non-fixed pulmonary infiltrates on radiography
- Paranasal sinus abnormality
- Biopsy demonstrating blood vessel eosinophilic infiltrates
Presence of at least two items confers 90% specificity while histology most reliably
distinguishes from hypereosinophilic syndromes lacking angiitis.
Immunopathogenesis
Though etiology remains unclear, leading hypotheses implicate:
- Genetic predisposition conveyed by HLA-DRB1*04 alleles and dysregulated T cell subsets
propagating Type 2 T-helper cell responses.
- Autoimmunity directed against self-antigens expressed on lung basement membranes
potentiating pathological eosinophilia.
- Aberrant signalling through interleukin-5, eotaxin and other eosinophilopoietic chemokines
elevating numbers/activation states.
- Eosinophil adhesion/recruitment factors directing migratory patterns towards tissues
releasing damage mediators.
- Complement activation downstream releasing C5a anaphylatoxin promoting angiogenesis
and endothelial damage.
Unraveling these pathogenic pathways informs targeted therapeutic approaches.
Treatment Strategies
In CSS, immunosuppression aims at disease control in remission induction then maintenance
phases:
- Induction reverses clinical manifestations/eosinophilia with pulsed intravenous
methylprednisolone then oral prednisone over months.
- Cytotoxic immunoablation utilizes cyclophosphamide pulsing to accelerate remission
attainment alongside glucocorticoids.
- Maintenance employs less toxic therapies minimizing relapses/complications including
azathioprine, methotrexate or mycophenolate mofetil.
- Refractory/relapsing disease warrants anti-IL5 monoclonal antibodies mepolizumab or
benralizumab depleting pathogenic eosinophils directly.
- Plasmapheresis rapidly clears autoantibodies/complement components during severe
alveolar hemorrhage or myocarditis crises.
Newer targeted molecules inhibiting specific T-cell subsets, chemokines or complement
pathways present promising adjuncts.
Challenges and Unresolved Questions
With survivorship improved, priorities emerge addressing:
- Defining predictive biomarkers guiding individualized induction/maintenance durations
limiting cumulative toxicity.
- Addressing cardiac remodeling preventing dilated cardiomyopathy contributing to long-
term mortality.
- Optimizing neuroprotective strategies halting small fiber neuropathy progression impairing
quality of life.
- Clarifying whether hypereosinophilia denotes pre-staging or phenotypic variant from
angiitis-associated CSS.
- Identifying environmental/infectious triggers breaking tolerance specifically in atopic
individuals.
- Determining whether antigen-specific immune deviations perpetuate relapsing cycles
amenable to tolerance induction.
Ongoing mechanistic studies addressing these uncertainties will translate to personalized
precision therapy optimizing outcomes.
Concluding Remarks
As an organ-damaging eosinophil-associated vasculitis, CSS showcases immunology's
complexity regulating inflammation. Considerable progress defined diagnostic criteria,
induced safer remissions yet preventing relapses/complications demands further tailored
therapies. Multi-omic studies discerning pathogenic leukocyte, cytokine and autoantibody
networks across subphenotypes will guide stratification into minimalistic targeted regimens.
Leveraging genetic risk loci may preemptively interrupt disease cascades before irreversible
injury occurs. Overall, elucidating CSS's molecular underpinnings holds promise refining
precision management for an enigmatic though medically actionable syndrome.
As a rare multi-system vasculitic disorder associated with asthma and peripheral blood
eosinophilia, Churg-Strauss syndrome (CSS) highlights complex immune interactions
underlying chronic inflammation. Named for the pathologists describing its pulmonary
pathology in 1951, CSS predominantly afflicts the lungs, heart and nerves yet remains poorly
understood. While glucocorticoids induce remission, relapses demand judicious
immunosuppression. Molecular mechanisms continue elucidating pathogenic eosinophilia,
elucidating new therapeutic angles. This review describes CSS clinical spectrum,
histopathology, criteria for diagnosis and the evolving immunological backdrop against
which treatment continues optimization.
Clinical Presentations
CSS involves multiple organs through variable symptoms constituting four distinct phases:
- Prodromal Asthma: Persistent allergic rhinitis, asthma diagnosed ≥6
months prior onset dominates here.
- Eosinophilic Phase: Marked blood/tissue eosinophilia with pulmonary infiltrates and
cardiomyopathy potentially lethal if untreated.
- Vasculitic Phase: Mononeuritis multiplex, alveolar hemorrhage, glomerulonephritis from
small/medium vessel necrotizing angiitis arise.
- Refractory Phase: Rare untreated patients display granulomatous involvement of lungs,
heart, kidney with fibrosis complicating long-term outcomes.
Manifestations arise from circulating and tissue-infiltrating eosinophils causing endothelial
damage and ischemic tissue injury vis complement activation, releasing toxic granule
proteins and reactive oxygen species.
Histopathology
Biopsies variably display:
- Pulmonary: Eosinophilic pneumonia with interstitial/intra-alveolar infiltrates and
eosinophilic abscesses.
- Peripheral Nerve: Mononuclear perineuritis prominently involving vasculitic nerves.
- Myocardium: Epicardial, endocardial eosinophilic infiltrates with fibrotic remodeling of
myocardial architecture over time.
- Kidney: Focal necrotizing glomerulonephritis with extracapillary proliferation and crescent
formation.
Eosinophil-rich inflammatory foci intermixed with necrotizing vascular lesions propagate
multi-organ injury here.
Diagnostic Criteria
American College of Rheumatology consensus diagnosis requires four or more items
including:
- Asthma
- Eosinophilia >10% on differential
- Mononeuropathy (including multiplex) or polyneuropathy
- Non-fixed pulmonary infiltrates on radiography
- Paranasal sinus abnormality
- Biopsy demonstrating blood vessel eosinophilic infiltrates
Presence of at least two items confers 90% specificity while histology most reliably
distinguishes from hypereosinophilic syndromes lacking angiitis.
Immunopathogenesis
Though etiology remains unclear, leading hypotheses implicate:
- Genetic predisposition conveyed by HLA-DRB1*04 alleles and dysregulated T cell subsets
propagating Type 2 T-helper cell responses.
- Autoimmunity directed against self-antigens expressed on lung basement membranes
potentiating pathological eosinophilia.
- Aberrant signalling through interleukin-5, eotaxin and other eosinophilopoietic chemokines
elevating numbers/activation states.
- Eosinophil adhesion/recruitment factors directing migratory patterns towards tissues
releasing damage mediators.
- Complement activation downstream releasing C5a anaphylatoxin promoting angiogenesis
and endothelial damage.
Unraveling these pathogenic pathways informs targeted therapeutic approaches.
Treatment Strategies
In CSS, immunosuppression aims at disease control in remission induction then maintenance
phases:
- Induction reverses clinical manifestations/eosinophilia with pulsed intravenous
methylprednisolone then oral prednisone over months.
- Cytotoxic immunoablation utilizes cyclophosphamide pulsing to accelerate remission
attainment alongside glucocorticoids.
- Maintenance employs less toxic therapies minimizing relapses/complications including
azathioprine, methotrexate or mycophenolate mofetil.
- Refractory/relapsing disease warrants anti-IL5 monoclonal antibodies mepolizumab or
benralizumab depleting pathogenic eosinophils directly.
- Plasmapheresis rapidly clears autoantibodies/complement components during severe
alveolar hemorrhage or myocarditis crises.
Newer targeted molecules inhibiting specific T-cell subsets, chemokines or complement
pathways present promising adjuncts.
Challenges and Unresolved Questions
With survivorship improved, priorities emerge addressing:
- Defining predictive biomarkers guiding individualized induction/maintenance durations
limiting cumulative toxicity.
- Addressing cardiac remodeling preventing dilated cardiomyopathy contributing to long-
term mortality.
- Optimizing neuroprotective strategies halting small fiber neuropathy progression impairing
quality of life.
- Clarifying whether hypereosinophilia denotes pre-staging or phenotypic variant from
angiitis-associated CSS.
- Identifying environmental/infectious triggers breaking tolerance specifically in atopic
individuals.
- Determining whether antigen-specific immune deviations perpetuate relapsing cycles
amenable to tolerance induction.
Ongoing mechanistic studies addressing these uncertainties will translate to personalized
precision therapy optimizing outcomes.
Concluding Remarks
As an organ-damaging eosinophil-associated vasculitis, CSS showcases immunology's
complexity regulating inflammation. Considerable progress defined diagnostic criteria,
induced safer remissions yet preventing relapses/complications demands further tailored
therapies. Multi-omic studies discerning pathogenic leukocyte, cytokine and autoantibody
networks across subphenotypes will guide stratification into minimalistic targeted regimens.
Leveraging genetic risk loci may preemptively interrupt disease cascades before irreversible
injury occurs. Overall, elucidating CSS's molecular underpinnings holds promise refining
precision management for an enigmatic though medically actionable syndrome.
As a rare multi-system vasculitic disorder associated with asthma and peripheral blood
eosinophilia, Churg-Strauss syndrome (CSS) highlights complex immune interactions
underlying chronic inflammation. Named for the pathologists describing its pulmonary
pathology in 1951, CSS predominantly afflicts the lungs, heart and nerves yet remains poorly
understood. While glucocorticoids induce remission, relapses demand judicious
immunosuppression. Molecular mechanisms continue elucidating pathogenic eosinophilia,
elucidating new therapeutic angles. This review describes CSS clinical spectrum,
histopathology, criteria for diagnosis and the evolving immunological backdrop against
which treatment continues optimization.
Clinical Presentations
CSS involves multiple organs through variable symptoms constituting four distinct phases:
- Prodromal Asthma: Persistent allergic rhinitis, asthma diagnosed ≥6
months prior onset dominates here.
- Eosinophilic Phase: Marked blood/tissue eosinophilia with pulmonary infiltrates and
cardiomyopathy potentially lethal if untreated.
- Vasculitic Phase: Mononeuritis multiplex, alveolar hemorrhage, glomerulonephritis from
small/medium vessel necrotizing angiitis arise.
- Refractory Phase: Rare untreated patients display granulomatous involvement of lungs,
heart, kidney with fibrosis complicating long-term outcomes.
Manifestations arise from circulating and tissue-infiltrating eosinophils causing endothelial
damage and ischemic tissue injury vis complement activation, releasing toxic granule
proteins and reactive oxygen species.
Histopathology
Biopsies variably display:
- Pulmonary: Eosinophilic pneumonia with interstitial/intra-alveolar infiltrates and
eosinophilic abscesses.
- Peripheral Nerve: Mononuclear perineuritis prominently involving vasculitic nerves.
- Myocardium: Epicardial, endocardial eosinophilic infiltrates with fibrotic remodeling of
myocardial architecture over time.
- Kidney: Focal necrotizing glomerulonephritis with extracapillary proliferation and crescent
formation.
Eosinophil-rich inflammatory foci intermixed with necrotizing vascular lesions propagate
multi-organ injury here.
Diagnostic Criteria
American College of Rheumatology consensus diagnosis requires four or more items
including:
- Asthma
- Eosinophilia >10% on differential
- Mononeuropathy (including multiplex) or polyneuropathy
- Non-fixed pulmonary infiltrates on radiography
- Paranasal sinus abnormality
- Biopsy demonstrating blood vessel eosinophilic infiltrates
Presence of at least two items confers 90% specificity while histology most reliably
distinguishes from hypereosinophilic syndromes lacking angiitis.
Immunopathogenesis
Though etiology remains unclear, leading hypotheses implicate:
- Genetic predisposition conveyed by HLA-DRB1*04 alleles and dysregulated T cell subsets
propagating Type 2 T-helper cell responses.
- Autoimmunity directed against self-antigens expressed on lung basement membranes
potentiating pathological eosinophilia.
- Aberrant signalling through interleukin-5, eotaxin and other eosinophilopoietic chemokines
elevating numbers/activation states.
- Eosinophil adhesion/recruitment factors directing migratory patterns towards tissues
releasing damage mediators.
- Complement activation downstream releasing C5a anaphylatoxin promoting angiogenesis
and endothelial damage.
Unraveling these pathogenic pathways informs targeted therapeutic approaches.
Treatment Strategies
In CSS, immunosuppression aims at disease control in remission induction then maintenance
phases:
- Induction reverses clinical manifestations/eosinophilia with pulsed intravenous
methylprednisolone then oral prednisone over months.
- Cytotoxic immunoablation utilizes cyclophosphamide pulsing to accelerate remission
attainment alongside glucocorticoids.
- Maintenance employs less toxic therapies minimizing relapses/complications including
azathioprine, methotrexate or mycophenolate mofetil.
- Refractory/relapsing disease warrants anti-IL5 monoclonal antibodies mepolizumab or
benralizumab depleting pathogenic eosinophils directly.
- Plasmapheresis rapidly clears autoantibodies/complement components during severe
alveolar hemorrhage or myocarditis crises.
Newer targeted molecules inhibiting specific T-cell subsets, chemokines or complement
pathways present promising adjuncts.
Challenges and Unresolved Questions
With survivorship improved, priorities emerge addressing:
- Defining predictive biomarkers guiding individualized induction/maintenance durations
limiting cumulative toxicity.
- Addressing cardiac remodeling preventing dilated cardiomyopathy contributing to long-
term mortality.
- Optimizing neuroprotective strategies halting small fiber neuropathy progression impairing
quality of life.
- Clarifying whether hypereosinophilia denotes pre-staging or phenotypic variant from
angiitis-associated CSS.
- Identifying environmental/infectious triggers breaking tolerance specifically in atopic
individuals.
- Determining whether antigen-specific immune deviations perpetuate relapsing cycles
amenable to tolerance induction.
Ongoing mechanistic studies addressing these uncertainties will translate to personalized
precision therapy optimizing outcomes.
Concluding Remarks
As an organ-damaging eosinophil-associated vasculitis, CSS showcases immunology's
complexity regulating inflammation. Considerable progress defined diagnostic criteria,
induced safer remissions yet preventing relapses/complications demands further tailored
therapies. Multi-omic studies discerning pathogenic leukocyte, cytokine and autoantibody
networks across subphenotypes will guide stratification into minimalistic targeted regimens.
Leveraging genetic risk loci may preemptively interrupt disease cascades before irreversible
injury occurs. Overall, elucidating CSS's molecular underpinnings holds promise refining
precision management for an enigmatic though medically actionable syndrome.
As a rare multi-system vasculitic disorder associated with asthma and peripheral blood
eosinophilia, Churg-Strauss syndrome (CSS) highlights complex immune interactions
underlying chronic inflammation. Named for the pathologists describing its pulmonary
pathology in 1951, CSS predominantly afflicts the lungs, heart and nerves yet remains poorly
understood. While glucocorticoids induce remission, relapses demand judicious
immunosuppression. Molecular mechanisms continue elucidating pathogenic eosinophilia,
elucidating new therapeutic angles. This review describes CSS clinical spectrum,
histopathology, criteria for diagnosis and the evolving immunological backdrop against
which treatment continues optimization.
Clinical Presentations
CSS involves multiple organs through variable symptoms constituting four distinct phases:
- Prodromal Asthma: Persistent allergic rhinitis, asthma diagnosed ≥6
months prior onset dominates here.
- Eosinophilic Phase: Marked blood/tissue eosinophilia with pulmonary infiltrates and
cardiomyopathy potentially lethal if untreated.
- Vasculitic Phase: Mononeuritis multiplex, alveolar hemorrhage, glomerulonephritis from
small/medium vessel necrotizing angiitis arise.
- Refractory Phase: Rare untreated patients display granulomatous involvement of lungs,
heart, kidney with fibrosis complicating long-term outcomes.
Manifestations arise from circulating and tissue-infiltrating eosinophils causing endothelial
damage and ischemic tissue injury vis complement activation, releasing toxic granule
proteins and reactive oxygen species.
Histopathology
Biopsies variably display:
- Pulmonary: Eosinophilic pneumonia with interstitial/intra-alveolar infiltrates and
eosinophilic abscesses.
- Peripheral Nerve: Mononuclear perineuritis prominently involving vasculitic nerves.
- Myocardium: Epicardial, endocardial eosinophilic infiltrates with fibrotic remodeling of
myocardial architecture over time.
- Kidney: Focal necrotizing glomerulonephritis with extracapillary proliferation and crescent
formation.
Eosinophil-rich inflammatory foci intermixed with necrotizing vascular lesions propagate
multi-organ injury here.
Diagnostic Criteria
American College of Rheumatology consensus diagnosis requires four or more items
including:
- Asthma
- Eosinophilia >10% on differential
- Mononeuropathy (including multiplex) or polyneuropathy
- Non-fixed pulmonary infiltrates on radiography
- Paranasal sinus abnormality
- Biopsy demonstrating blood vessel eosinophilic infiltrates
Presence of at least two items confers 90% specificity while histology most reliably
distinguishes from hypereosinophilic syndromes lacking angiitis.
Immunopathogenesis
Though etiology remains unclear, leading hypotheses implicate:
- Genetic predisposition conveyed by HLA-DRB1*04 alleles and dysregulated T cell subsets
propagating Type 2 T-helper cell responses.
- Autoimmunity directed against self-antigens expressed on lung basement membranes
potentiating pathological eosinophilia.
- Aberrant signalling through interleukin-5, eotaxin and other eosinophilopoietic chemokines
elevating numbers/activation states.
- Eosinophil adhesion/recruitment factors directing migratory patterns towards tissues
releasing damage mediators.
- Complement activation downstream releasing C5a anaphylatoxin promoting angiogenesis
and endothelial damage.
Unraveling these pathogenic pathways informs targeted therapeutic approaches.
Treatment Strategies
In CSS, immunosuppression aims at disease control in remission induction then maintenance
phases:
- Induction reverses clinical manifestations/eosinophilia with pulsed intravenous
methylprednisolone then oral prednisone over months.
- Cytotoxic immunoablation utilizes cyclophosphamide pulsing to accelerate remission
attainment alongside glucocorticoids.
- Maintenance employs less toxic therapies minimizing relapses/complications including
azathioprine, methotrexate or mycophenolate mofetil.
- Refractory/relapsing disease warrants anti-IL5 monoclonal antibodies mepolizumab or
benralizumab depleting pathogenic eosinophils directly.
- Plasmapheresis rapidly clears autoantibodies/complement components during severe
alveolar hemorrhage or myocarditis crises.
Newer targeted molecules inhibiting specific T-cell subsets, chemokines or complement
pathways present promising adjuncts.
Challenges and Unresolved Questions
With survivorship improved, priorities emerge addressing:
- Defining predictive biomarkers guiding individualized induction/maintenance durations
limiting cumulative toxicity.
- Addressing cardiac remodeling preventing dilated cardiomyopathy contributing to long-
term mortality.
- Optimizing neuroprotective strategies halting small fiber neuropathy progression impairing
quality of life.
- Clarifying whether hypereosinophilia denotes pre-staging or phenotypic variant from
angiitis-associated CSS.
- Identifying environmental/infectious triggers breaking tolerance specifically in atopic
individuals.
- Determining whether antigen-specific immune deviations perpetuate relapsing cycles
amenable to tolerance induction.
Ongoing mechanistic studies addressing these uncertainties will translate to personalized
precision therapy optimizing outcomes.
Concluding Remarks
As an organ-damaging eosinophil-associated vasculitis, CSS showcases immunology's
complexity regulating inflammation. Considerable progress defined diagnostic criteria,
induced safer remissions yet preventing relapses/complications demands further tailored
therapies. Multi-omic studies discerning pathogenic leukocyte, cytokine and autoantibody
networks across subphenotypes will guide stratification into minimalistic targeted regimens.
Leveraging genetic risk loci may preemptively interrupt disease cascades before irreversible
injury occurs. Overall, elucidating CSS's molecular underpinnings holds promise refining
precision management for an enigmatic though medically actionable syndrome.
As a rare multi-system vasculitic disorder associated with asthma and peripheral blood
eosinophilia, Churg-Strauss syndrome (CSS) highlights complex immune interactions
underlying chronic inflammation. Named for the pathologists describing its pulmonary
pathology in 1951, CSS predominantly afflicts the lungs, heart and nerves yet remains poorly
understood. While glucocorticoids induce remission, relapses demand judicious
immunosuppression. Molecular mechanisms continue elucidating pathogenic eosinophilia,
elucidating new therapeutic angles. This review describes CSS clinical spectrum,
histopathology, criteria for diagnosis and the evolving immunological backdrop against
which treatment continues optimization.
Clinical Presentations
CSS involves multiple organs through variable symptoms constituting four distinct phases:
- Prodromal Asthma: Persistent allergic rhinitis, asthma diagnosed ≥6
months prior onset dominates here.
- Eosinophilic Phase: Marked blood/tissue eosinophilia with pulmonary infiltrates and
cardiomyopathy potentially lethal if untreated.
- Vasculitic Phase: Mononeuritis multiplex, alveolar hemorrhage, glomerulonephritis from
small/medium vessel necrotizing angiitis arise.
- Refractory Phase: Rare untreated patients display granulomatous involvement of lungs,
heart, kidney with fibrosis complicating long-term outcomes.
Manifestations arise from circulating and tissue-infiltrating eosinophils causing endothelial
damage and ischemic tissue injury vis complement activation, releasing toxic granule
proteins and reactive oxygen species.
Histopathology
Biopsies variably display:
- Pulmonary: Eosinophilic pneumonia with interstitial/intra-alveolar infiltrates and
eosinophilic abscesses.
- Peripheral Nerve: Mononuclear perineuritis prominently involving vasculitic nerves.
- Myocardium: Epicardial, endocardial eosinophilic infiltrates with fibrotic remodeling of
myocardial architecture over time.
- Kidney: Focal necrotizing glomerulonephritis with extracapillary proliferation and crescent
formation.
Eosinophil-rich inflammatory foci intermixed with necrotizing vascular lesions propagate
multi-organ injury here.
Diagnostic Criteria
American College of Rheumatology consensus diagnosis requires four or more items
including:
- Asthma
- Eosinophilia >10% on differential
- Mononeuropathy (including multiplex) or polyneuropathy
- Non-fixed pulmonary infiltrates on radiography
- Paranasal sinus abnormality
- Biopsy demonstrating blood vessel eosinophilic infiltrates
Presence of at least two items confers 90% specificity while histology most reliably
distinguishes from hypereosinophilic syndromes lacking angiitis.
Immunopathogenesis
Though etiology remains unclear, leading hypotheses implicate:
- Genetic predisposition conveyed by HLA-DRB1*04 alleles and dysregulated T cell subsets
propagating Type 2 T-helper cell responses.
- Autoimmunity directed against self-antigens expressed on lung basement membranes
potentiating pathological eosinophilia.
- Aberrant signalling through interleukin-5, eotaxin and other eosinophilopoietic chemokines
elevating numbers/activation states.
- Eosinophil adhesion/recruitment factors directing migratory patterns towards tissues
releasing damage mediators.
- Complement activation downstream releasing C5a anaphylatoxin promoting angiogenesis
and endothelial damage.
Unraveling these pathogenic pathways informs targeted therapeutic approaches.
Treatment Strategies
In CSS, immunosuppression aims at disease control in remission induction then maintenance
phases:
- Induction reverses clinical manifestations/eosinophilia with pulsed intravenous
methylprednisolone then oral prednisone over months.
- Cytotoxic immunoablation utilizes cyclophosphamide pulsing to accelerate remission
attainment alongside glucocorticoids.
- Maintenance employs less toxic therapies minimizing relapses/complications including
azathioprine, methotrexate or mycophenolate mofetil.
- Refractory/relapsing disease warrants anti-IL5 monoclonal antibodies mepolizumab or
benralizumab depleting pathogenic eosinophils directly.
- Plasmapheresis rapidly clears autoantibodies/complement components during severe
alveolar hemorrhage or myocarditis crises.
Newer targeted molecules inhibiting specific T-cell subsets, chemokines or complement
pathways present promising adjuncts.
Challenges and Unresolved Questions
With survivorship improved, priorities emerge addressing:
- Defining predictive biomarkers guiding individualized induction/maintenance durations
limiting cumulative toxicity.
- Addressing cardiac remodeling preventing dilated cardiomyopathy contributing to long-
term mortality.
- Optimizing neuroprotective strategies halting small fiber neuropathy progression impairing
quality of life.
- Clarifying whether hypereosinophilia denotes pre-staging or phenotypic variant from
angiitis-associated CSS.
- Identifying environmental/infectious triggers breaking tolerance specifically in atopic
individuals.
- Determining whether antigen-specific immune deviations perpetuate relapsing cycles
amenable to tolerance induction.
Ongoing mechanistic studies addressing these uncertainties will translate to personalized
precision therapy optimizing outcomes.
Concluding Remarks
As an organ-damaging eosinophil-associated vasculitis, CSS showcases immunology's
complexity regulating inflammation. Considerable progress defined diagnostic criteria,
induced safer remissions yet preventing relapses/complications demands further tailored
therapies. Multi-omic studies discerning pathogenic leukocyte, cytokine and autoantibody
networks across subphenotypes will guide stratification into minimalistic targeted regimens.
Leveraging genetic risk loci may preemptively interrupt disease cascades before irreversible
injury occurs. Overall, elucidating CSS's molecular underpinnings holds promise refining
precision management for an enigmatic though medically actionable syndrome.
As a rare multi-system vasculitic disorder associated with asthma and peripheral blood
eosinophilia, Churg-Strauss syndrome (CSS) highlights complex immune interactions
underlying chronic inflammation. Named for the pathologists describing its pulmonary
pathology in 1951, CSS predominantly afflicts the lungs, heart and nerves yet remains poorly
understood. While glucocorticoids induce remission, relapses demand judicious
immunosuppression. Molecular mechanisms continue elucidating pathogenic eosinophilia,
elucidating new therapeutic angles. This review describes CSS clinical spectrum,
histopathology, criteria for diagnosis and the evolving immunological backdrop against
which treatment continues optimization.
Clinical Presentations
CSS involves multiple organs through variable symptoms constituting four distinct phases:
- Prodromal Asthma: Persistent allergic rhinitis, asthma diagnosed ≥6
months prior onset dominates here.
- Eosinophilic Phase: Marked blood/tissue eosinophilia with pulmonary infiltrates and
cardiomyopathy potentially lethal if untreated.
- Vasculitic Phase: Mononeuritis multiplex, alveolar hemorrhage, glomerulonephritis from
small/medium vessel necrotizing angiitis arise.
- Refractory Phase: Rare untreated patients display granulomatous involvement of lungs,
heart, kidney with fibrosis complicating long-term outcomes.
Manifestations arise from circulating and tissue-infiltrating eosinophils causing endothelial
damage and ischemic tissue injury vis complement activation, releasing toxic granule
proteins and reactive oxygen species.
Histopathology
Biopsies variably display:
- Pulmonary: Eosinophilic pneumonia with interstitial/intra-alveolar infiltrates and
eosinophilic abscesses.
- Peripheral Nerve: Mononuclear perineuritis prominently involving vasculitic nerves.
- Myocardium: Epicardial, endocardial eosinophilic infiltrates with fibrotic remodeling of
myocardial architecture over time.
- Kidney: Focal necrotizing glomerulonephritis with extracapillary proliferation and crescent
formation.
Eosinophil-rich inflammatory foci intermixed with necrotizing vascular lesions propagate
multi-organ injury here.
Diagnostic Criteria
American College of Rheumatology consensus diagnosis requires four or more items
including:
- Asthma
- Eosinophilia >10% on differential
- Mononeuropathy (including multiplex) or polyneuropathy
- Non-fixed pulmonary infiltrates on radiography
- Paranasal sinus abnormality
- Biopsy demonstrating blood vessel eosinophilic infiltrates
Presence of at least two items confers 90% specificity while histology most reliably
distinguishes from hypereosinophilic syndromes lacking angiitis.
Immunopathogenesis
Though etiology remains unclear, leading hypotheses implicate:
- Genetic predisposition conveyed by HLA-DRB1*04 alleles and dysregulated T cell subsets
propagating Type 2 T-helper cell responses.
- Autoimmunity directed against self-antigens expressed on lung basement membranes
potentiating pathological eosinophilia.
- Aberrant signalling through interleukin-5, eotaxin and other eosinophilopoietic chemokines
elevating numbers/activation states.
- Eosinophil adhesion/recruitment factors directing migratory patterns towards tissues
releasing damage mediators.
- Complement activation downstream releasing C5a anaphylatoxin promoting angiogenesis
and endothelial damage.
Unraveling these pathogenic pathways informs targeted therapeutic approaches.
Treatment Strategies
In CSS, immunosuppression aims at disease control in remission induction then maintenance
phases:
- Induction reverses clinical manifestations/eosinophilia with pulsed intravenous
methylprednisolone then oral prednisone over months.
- Cytotoxic immunoablation utilizes cyclophosphamide pulsing to accelerate remission
attainment alongside glucocorticoids.
- Maintenance employs less toxic therapies minimizing relapses/complications including
azathioprine, methotrexate or mycophenolate mofetil.
- Refractory/relapsing disease warrants anti-IL5 monoclonal antibodies mepolizumab or
benralizumab depleting pathogenic eosinophils directly.
- Plasmapheresis rapidly clears autoantibodies/complement components during severe
alveolar hemorrhage or myocarditis crises.
Newer targeted molecules inhibiting specific T-cell subsets, chemokines or complement
pathways present promising adjuncts.
Challenges and Unresolved Questions
With survivorship improved, priorities emerge addressing:
- Defining predictive biomarkers guiding individualized induction/maintenance durations
limiting cumulative toxicity.
- Addressing cardiac remodeling preventing dilated cardiomyopathy contributing to long-
term mortality.
- Optimizing neuroprotective strategies halting small fiber neuropathy progression impairing
quality of life.
- Clarifying whether hypereosinophilia denotes pre-staging or phenotypic variant from
angiitis-associated CSS.
- Identifying environmental/infectious triggers breaking tolerance specifically in atopic
individuals.
- Determining whether antigen-specific immune deviations perpetuate relapsing cycles
amenable to tolerance induction.
Ongoing mechanistic studies addressing these uncertainties will translate to personalized
precision therapy optimizing outcomes.
Concluding Remarks
As an organ-damaging eosinophil-associated vasculitis, CSS showcases immunology's
complexity regulating inflammation. Considerable progress defined diagnostic criteria,
induced safer remissions yet preventing relapses/complications demands further tailored
therapies. Multi-omic studies discerning pathogenic leukocyte, cytokine and autoantibody
networks across subphenotypes will guide stratification into minimalistic targeted regimens.
Leveraging genetic risk loci may preemptively interrupt disease cascades before irreversible
injury occurs. Overall, elucidating CSS's molecular underpinnings holds promise refining
precision management for an enigmatic though medically actionable syndrome.
As a rare multi-system vasculitic disorder associated with asthma and peripheral blood
eosinophilia, Churg-Strauss syndrome (CSS) highlights complex immune interactions
underlying chronic inflammation. Named for the pathologists describing its pulmonary
pathology in 1951, CSS predominantly afflicts the lungs, heart and nerves yet remains poorly
understood. While glucocorticoids induce remission, relapses demand judicious
immunosuppression. Molecular mechanisms continue elucidating pathogenic eosinophilia,
elucidating new therapeutic angles. This review describes CSS clinical spectrum,
histopathology, criteria for diagnosis and the evolving immunological backdrop against
which treatment continues optimization.
Clinical Presentations
CSS involves multiple organs through variable symptoms constituting four distinct phases:
- Prodromal Asthma: Persistent allergic rhinitis, asthma diagnosed ≥6
months prior onset dominates here.
- Eosinophilic Phase: Marked blood/tissue eosinophilia with pulmonary infiltrates and
cardiomyopathy potentially lethal if untreated.
- Vasculitic Phase: Mononeuritis multiplex, alveolar hemorrhage, glomerulonephritis from
small/medium vessel necrotizing angiitis arise.
- Refractory Phase: Rare untreated patients display granulomatous involvement of lungs,
heart, kidney with fibrosis complicating long-term outcomes.
Manifestations arise from circulating and tissue-infiltrating eosinophils causing endothelial
damage and ischemic tissue injury vis complement activation, releasing toxic granule
proteins and reactive oxygen species.
Histopathology
Biopsies variably display:
- Pulmonary: Eosinophilic pneumonia with interstitial/intra-alveolar infiltrates and
eosinophilic abscesses.
- Peripheral Nerve: Mononuclear perineuritis prominently involving vasculitic nerves.
- Myocardium: Epicardial, endocardial eosinophilic infiltrates with fibrotic remodeling of
myocardial architecture over time.
- Kidney: Focal necrotizing glomerulonephritis with extracapillary proliferation and crescent
formation.
Eosinophil-rich inflammatory foci intermixed with necrotizing vascular lesions propagate
multi-organ injury here.
Diagnostic Criteria
American College of Rheumatology consensus diagnosis requires four or more items
including:
- Asthma
- Eosinophilia >10% on differential
- Mononeuropathy (including multiplex) or polyneuropathy
- Non-fixed pulmonary infiltrates on radiography
- Paranasal sinus abnormality
- Biopsy demonstrating blood vessel eosinophilic infiltrates
Presence of at least two items confers 90% specificity while histology most reliably
distinguishes from hypereosinophilic syndromes lacking angiitis.
Immunopathogenesis
Though etiology remains unclear, leading hypotheses implicate:
- Genetic predisposition conveyed by HLA-DRB1*04 alleles and dysregulated T cell subsets
propagating Type 2 T-helper cell responses.
- Autoimmunity directed against self-antigens expressed on lung basement membranes
potentiating pathological eosinophilia.
- Aberrant signalling through interleukin-5, eotaxin and other eosinophilopoietic chemokines
elevating numbers/activation states.
- Eosinophil adhesion/recruitment factors directing migratory patterns towards tissues
releasing damage mediators.
- Complement activation downstream releasing C5a anaphylatoxin promoting angiogenesis
and endothelial damage.
Unraveling these pathogenic pathways informs targeted therapeutic approaches.
Treatment Strategies
In CSS, immunosuppression aims at disease control in remission induction then maintenance
phases:
- Induction reverses clinical manifestations/eosinophilia with pulsed intravenous
methylprednisolone then oral prednisone over months.
- Cytotoxic immunoablation utilizes cyclophosphamide pulsing to accelerate remission
attainment alongside glucocorticoids.
- Maintenance employs less toxic therapies minimizing relapses/complications including
azathioprine, methotrexate or mycophenolate mofetil.
- Refractory/relapsing disease warrants anti-IL5 monoclonal antibodies mepolizumab or
benralizumab depleting pathogenic eosinophils directly.
- Plasmapheresis rapidly clears autoantibodies/complement components during severe
alveolar hemorrhage or myocarditis crises.
Newer targeted molecules inhibiting specific T-cell subsets, chemokines or complement
pathways present promising adjuncts.
Challenges and Unresolved Questions
With survivorship improved, priorities emerge addressing:
- Defining predictive biomarkers guiding individualized induction/maintenance durations
limiting cumulative toxicity.
- Addressing cardiac remodeling preventing dilated cardiomyopathy contributing to long-
term mortality.
- Optimizing neuroprotective strategies halting small fiber neuropathy progression impairing
quality of life.
- Clarifying whether hypereosinophilia denotes pre-staging or phenotypic variant from
angiitis-associated CSS.
- Identifying environmental/infectious triggers breaking tolerance specifically in atopic
individuals.
- Determining whether antigen-specific immune deviations perpetuate relapsing cycles
amenable to tolerance induction.
Ongoing mechanistic studies addressing these uncertainties will translate to personalized
precision therapy optimizing outcomes.
Concluding Remarks
As an organ-damaging eosinophil-associated vasculitis, CSS showcases immunology's
complexity regulating inflammation. Considerable progress defined diagnostic criteria,
induced safer remissions yet preventing relapses/complications demands further tailored
therapies. Multi-omic studies discerning pathogenic leukocyte, cytokine and autoantibody
networks across subphenotypes will guide stratification into minimalistic targeted regimens.
Leveraging genetic risk loci may preemptively interrupt disease cascades before irreversible
injury occurs. Overall, elucidating CSS's molecular underpinnings holds promise refining
precision management for an enigmatic though medically actionable syndrome.
As a rare multi-system vasculitic disorder associated with asthma and peripheral blood
eosinophilia, Churg-Strauss syndrome (CSS) highlights complex immune interactions
underlying chronic inflammation. Named for the pathologists describing its pulmonary
pathology in 1951, CSS predominantly afflicts the lungs, heart and nerves yet remains poorly
understood. While glucocorticoids induce remission, relapses demand judicious
immunosuppression. Molecular mechanisms continue elucidating pathogenic eosinophilia,
elucidating new therapeutic angles. This review describes CSS clinical spectrum,
histopathology, criteria for diagnosis and the evolving immunological backdrop against
which treatment continues optimization.
Clinical Presentations
CSS involves multiple organs through variable symptoms constituting four distinct phases:
- Prodromal Asthma: Persistent allergic rhinitis, asthma diagnosed ≥6
months prior onset dominates here.
- Eosinophilic Phase: Marked blood/tissue eosinophilia with pulmonary infiltrates and
cardiomyopathy potentially lethal if untreated.
- Vasculitic Phase: Mononeuritis multiplex, alveolar hemorrhage, glomerulonephritis from
small/medium vessel necrotizing angiitis arise.
- Refractory Phase: Rare untreated patients display granulomatous involvement of lungs,
heart, kidney with fibrosis complicating long-term outcomes.
Manifestations arise from circulating and tissue-infiltrating eosinophils causing endothelial
damage and ischemic tissue injury vis complement activation, releasing toxic granule
proteins and reactive oxygen species.
Histopathology
Biopsies variably display:
- Pulmonary: Eosinophilic pneumonia with interstitial/intra-alveolar infiltrates and
eosinophilic abscesses.
- Peripheral Nerve: Mononuclear perineuritis prominently involving vasculitic nerves.
- Myocardium: Epicardial, endocardial eosinophilic infiltrates with fibrotic remodeling of
myocardial architecture over time.
- Kidney: Focal necrotizing glomerulonephritis with extracapillary proliferation and crescent
formation.
Eosinophil-rich inflammatory foci intermixed with necrotizing vascular lesions propagate
multi-organ injury here.
Diagnostic Criteria
American College of Rheumatology consensus diagnosis requires four or more items
including:
- Asthma
- Eosinophilia >10% on differential
- Mononeuropathy (including multiplex) or polyneuropathy
- Non-fixed pulmonary infiltrates on radiography
- Paranasal sinus abnormality
- Biopsy demonstrating blood vessel eosinophilic infiltrates
Presence of at least two items confers 90% specificity while histology most reliably
distinguishes from hypereosinophilic syndromes lacking angiitis.
Immunopathogenesis
Though etiology remains unclear, leading hypotheses implicate:
- Genetic predisposition conveyed by HLA-DRB1*04 alleles and dysregulated T cell subsets
propagating Type 2 T-helper cell responses.
- Autoimmunity directed against self-antigens expressed on lung basement membranes
potentiating pathological eosinophilia.
- Aberrant signalling through interleukin-5, eotaxin and other eosinophilopoietic chemokines
elevating numbers/activation states.
- Eosinophil adhesion/recruitment factors directing migratory patterns towards tissues
releasing damage mediators.
- Complement activation downstream releasing C5a anaphylatoxin promoting angiogenesis
and endothelial damage.
Unraveling these pathogenic pathways informs targeted therapeutic approaches.
Treatment Strategies
In CSS, immunosuppression aims at disease control in remission induction then maintenance
phases:
- Induction reverses clinical manifestations/eosinophilia with pulsed intravenous
methylprednisolone then oral prednisone over months.
- Cytotoxic immunoablation utilizes cyclophosphamide pulsing to accelerate remission
attainment alongside glucocorticoids.
- Maintenance employs less toxic therapies minimizing relapses/complications including
azathioprine, methotrexate or mycophenolate mofetil.
- Refractory/relapsing disease warrants anti-IL5 monoclonal antibodies mepolizumab or
benralizumab depleting pathogenic eosinophils directly.
- Plasmapheresis rapidly clears autoantibodies/complement components during severe
alveolar hemorrhage or myocarditis crises.
Newer targeted molecules inhibiting specific T-cell subsets, chemokines or complement
pathways present promising adjuncts.
Challenges and Unresolved Questions
With survivorship improved, priorities emerge addressing:
- Defining predictive biomarkers guiding individualized induction/maintenance durations
limiting cumulative toxicity.
- Addressing cardiac remodeling preventing dilated cardiomyopathy contributing to long-
term mortality.
- Optimizing neuroprotective strategies halting small fiber neuropathy progression impairing
quality of life.
- Clarifying whether hypereosinophilia denotes pre-staging or phenotypic variant from
angiitis-associated CSS.
- Identifying environmental/infectious triggers breaking tolerance specifically in atopic
individuals.
- Determining whether antigen-specific immune deviations perpetuate relapsing cycles
amenable to tolerance induction.
Ongoing mechanistic studies addressing these uncertainties will translate to personalized
precision therapy optimizing outcomes.
Concluding Remarks
As an organ-damaging eosinophil-associated vasculitis, CSS showcases immunology's
complexity regulating inflammation. Considerable progress defined diagnostic criteria,
induced safer remissions yet preventing relapses/complications demands further tailored
therapies. Multi-omic studies discerning pathogenic leukocyte, cytokine and autoantibody
networks across subphenotypes will guide stratification into minimalistic targeted regimens.
Leveraging genetic risk loci may preemptively interrupt disease cascades before irreversible
injury occurs. Overall, elucidating CSS's molecular underpinnings holds promise refining
precision management for an enigmatic though medically actionable syndrome.
As a rare multi-system vasculitic disorder associated with asthma and peripheral blood
eosinophilia, Churg-Strauss syndrome (CSS) highlights complex immune interactions
underlying chronic inflammation. Named for the pathologists describing its pulmonary
pathology in 1951, CSS predominantly afflicts the lungs, heart and nerves yet remains poorly
understood. While glucocorticoids induce remission, relapses demand judicious
immunosuppression. Molecular mechanisms continue elucidating pathogenic eosinophilia,
elucidating new therapeutic angles. This review describes CSS clinical spectrum,
histopathology, criteria for diagnosis and the evolving immunological backdrop against
which treatment continues optimization.
Clinical Presentations
CSS involves multiple organs through variable symptoms constituting four distinct phases:
- Prodromal Asthma: Persistent allergic rhinitis, asthma diagnosed ≥6
months prior onset dominates here.
- Eosinophilic Phase: Marked blood/tissue eosinophilia with pulmonary infiltrates and
cardiomyopathy potentially lethal if untreated.
- Vasculitic Phase: Mononeuritis multiplex, alveolar hemorrhage, glomerulonephritis from
small/medium vessel necrotizing angiitis arise.
- Refractory Phase: Rare untreated patients display granulomatous involvement of lungs,
heart, kidney with fibrosis complicating long-term outcomes.
Manifestations arise from circulating and tissue-infiltrating eosinophils causing endothelial
damage and ischemic tissue injury vis complement activation, releasing toxic granule
proteins and reactive oxygen species.
Histopathology
Biopsies variably display:
- Pulmonary: Eosinophilic pneumonia with interstitial/intra-alveolar infiltrates and
eosinophilic abscesses.
- Peripheral Nerve: Mononuclear perineuritis prominently involving vasculitic nerves.
- Myocardium: Epicardial, endocardial eosinophilic infiltrates with fibrotic remodeling of
myocardial architecture over time.
- Kidney: Focal necrotizing glomerulonephritis with extracapillary proliferation and crescent
formation.
Eosinophil-rich inflammatory foci intermixed with necrotizing vascular lesions propagate
multi-organ injury here.
Diagnostic Criteria
American College of Rheumatology consensus diagnosis requires four or more items
including:
- Asthma
- Eosinophilia >10% on differential
- Mononeuropathy (including multiplex) or polyneuropathy
- Non-fixed pulmonary infiltrates on radiography
- Paranasal sinus abnormality
- Biopsy demonstrating blood vessel eosinophilic infiltrates
Presence of at least two items confers 90% specificity while histology most reliably
distinguishes from hypereosinophilic syndromes lacking angiitis.
Immunopathogenesis
Though etiology remains unclear, leading hypotheses implicate:
- Genetic predisposition conveyed by HLA-DRB1*04 alleles and dysregulated T cell subsets
propagating Type 2 T-helper cell responses.
- Autoimmunity directed against self-antigens expressed on lung basement membranes
potentiating pathological eosinophilia.
- Aberrant signalling through interleukin-5, eotaxin and other eosinophilopoietic chemokines
elevating numbers/activation states.
- Eosinophil adhesion/recruitment factors directing migratory patterns towards tissues
releasing damage mediators.
- Complement activation downstream releasing C5a anaphylatoxin promoting angiogenesis
and endothelial damage.
Unraveling these pathogenic pathways informs targeted therapeutic approaches.
Treatment Strategies
In CSS, immunosuppression aims at disease control in remission induction then maintenance
phases:
- Induction reverses clinical manifestations/eosinophilia with pulsed intravenous
methylprednisolone then oral prednisone over months.
- Cytotoxic immunoablation utilizes cyclophosphamide pulsing to accelerate remission
attainment alongside glucocorticoids.
- Maintenance employs less toxic therapies minimizing relapses/complications including
azathioprine, methotrexate or mycophenolate mofetil.
- Refractory/relapsing disease warrants anti-IL5 monoclonal antibodies mepolizumab or
benralizumab depleting pathogenic eosinophils directly.
- Plasmapheresis rapidly clears autoantibodies/complement components during severe
alveolar hemorrhage or myocarditis crises.
Newer targeted molecules inhibiting specific T-cell subsets, chemokines or complement
pathways present promising adjuncts.
Challenges and Unresolved Questions
With survivorship improved, priorities emerge addressing:
- Defining predictive biomarkers guiding individualized induction/maintenance durations
limiting cumulative toxicity.
- Addressing cardiac remodeling preventing dilated cardiomyopathy contributing to long-
term mortality.
- Optimizing neuroprotective strategies halting small fiber neuropathy progression impairing
quality of life.
- Clarifying whether hypereosinophilia denotes pre-staging or phenotypic variant from
angiitis-associated CSS.
- Identifying environmental/infectious triggers breaking tolerance specifically in atopic
individuals.
- Determining whether antigen-specific immune deviations perpetuate relapsing cycles
amenable to tolerance induction.
Ongoing mechanistic studies addressing these uncertainties will translate to personalized
precision therapy optimizing outcomes.
Concluding Remarks
As an organ-damaging eosinophil-associated vasculitis, CSS showcases immunology's
complexity regulating inflammation. Considerable progress defined diagnostic criteria,
induced safer remissions yet preventing relapses/complications demands further tailored
therapies. Multi-omic studies discerning pathogenic leukocyte, cytokine and autoantibody
networks across subphenotypes will guide stratification into minimalistic targeted regimens.
Leveraging genetic risk loci may preemptively interrupt disease cascades before irreversible
injury occurs. Overall, elucidating CSS's molecular underpinnings holds promise refining
precision management for an enigmatic though medically actionable syndrome.
As a rare multi-system vasculitic disorder associated with asthma and peripheral blood
eosinophilia, Churg-Strauss syndrome (CSS) highlights complex immune interactions
underlying chronic inflammation. Named for the pathologists describing its pulmonary
pathology in 1951, CSS predominantly afflicts the lungs, heart and nerves yet remains poorly
understood. While glucocorticoids induce remission, relapses demand judicious
immunosuppression. Molecular mechanisms continue elucidating pathogenic eosinophilia,
elucidating new therapeutic angles. This review describes CSS clinical spectrum,
histopathology, criteria for diagnosis and the evolving immunological backdrop against
which treatment continues optimization.
Clinical Presentations
CSS involves multiple organs through variable symptoms constituting four distinct phases:
- Prodromal Asthma: Persistent allergic rhinitis, asthma diagnosed ≥6
months prior onset dominates here.
- Eosinophilic Phase: Marked blood/tissue eosinophilia with pulmonary infiltrates and
cardiomyopathy potentially lethal if untreated.
- Vasculitic Phase: Mononeuritis multiplex, alveolar hemorrhage, glomerulonephritis from
small/medium vessel necrotizing angiitis arise.
- Refractory Phase: Rare untreated patients display granulomatous involvement of lungs,
heart, kidney with fibrosis complicating long-term outcomes.
Manifestations arise from circulating and tissue-infiltrating eosinophils causing endothelial
damage and ischemic tissue injury vis complement activation, releasing toxic granule
proteins and reactive oxygen species.
Histopathology
Biopsies variably display:
- Pulmonary: Eosinophilic pneumonia with interstitial/intra-alveolar infiltrates and
eosinophilic abscesses.
- Peripheral Nerve: Mononuclear perineuritis prominently involving vasculitic nerves.
- Myocardium: Epicardial, endocardial eosinophilic infiltrates with fibrotic remodeling of
myocardial architecture over time.
- Kidney: Focal necrotizing glomerulonephritis with extracapillary proliferation and crescent
formation.
Eosinophil-rich inflammatory foci intermixed with necrotizing vascular lesions propagate
multi-organ injury here.
Diagnostic Criteria
American College of Rheumatology consensus diagnosis requires four or more items
including:
- Asthma
- Eosinophilia >10% on differential
- Mononeuropathy (including multiplex) or polyneuropathy
- Non-fixed pulmonary infiltrates on radiography
- Paranasal sinus abnormality
- Biopsy demonstrating blood vessel eosinophilic infiltrates
Presence of at least two items confers 90% specificity while histology most reliably
distinguishes from hypereosinophilic syndromes lacking angiitis.
Immunopathogenesis
Though etiology remains unclear, leading hypotheses implicate:
- Genetic predisposition conveyed by HLA-DRB1*04 alleles and dysregulated T cell subsets
propagating Type 2 T-helper cell responses.
- Autoimmunity directed against self-antigens expressed on lung basement membranes
potentiating pathological eosinophilia.
- Aberrant signalling through interleukin-5, eotaxin and other eosinophilopoietic chemokines
elevating numbers/activation states.
- Eosinophil adhesion/recruitment factors directing migratory patterns towards tissues
releasing damage mediators.
- Complement activation downstream releasing C5a anaphylatoxin promoting angiogenesis
and endothelial damage.
Unraveling these pathogenic pathways informs targeted therapeutic approaches.
Treatment Strategies
In CSS, immunosuppression aims at disease control in remission induction then maintenance
phases:
- Induction reverses clinical manifestations/eosinophilia with pulsed intravenous
methylprednisolone then oral prednisone over months.
- Cytotoxic immunoablation utilizes cyclophosphamide pulsing to accelerate remission
attainment alongside glucocorticoids.
- Maintenance employs less toxic therapies minimizing relapses/complications including
azathioprine, methotrexate or mycophenolate mofetil.
- Refractory/relapsing disease warrants anti-IL5 monoclonal antibodies mepolizumab or
benralizumab depleting pathogenic eosinophils directly.
- Plasmapheresis rapidly clears autoantibodies/complement components during severe
alveolar hemorrhage or myocarditis crises.
Newer targeted molecules inhibiting specific T-cell subsets, chemokines or complement
pathways present promising adjuncts.
Challenges and Unresolved Questions
With survivorship improved, priorities emerge addressing:
- Defining predictive biomarkers guiding individualized induction/maintenance durations
limiting cumulative toxicity.
- Addressing cardiac remodeling preventing dilated cardiomyopathy contributing to long-
term mortality.
- Optimizing neuroprotective strategies halting small fiber neuropathy progression impairing
quality of life.
- Clarifying whether hypereosinophilia denotes pre-staging or phenotypic variant from
angiitis-associated CSS.
- Identifying environmental/infectious triggers breaking tolerance specifically in atopic
individuals.
- Determining whether antigen-specific immune deviations perpetuate relapsing cycles
amenable to tolerance induction.
Ongoing mechanistic studies addressing these uncertainties will translate to personalized
precision therapy optimizing outcomes.
Concluding Remarks
As an organ-damaging eosinophil-associated vasculitis, CSS showcases immunology's
complexity regulating inflammation. Considerable progress defined diagnostic criteria,
induced safer remissions yet preventing relapses/complications demands further tailored
therapies. Multi-omic studies discerning pathogenic leukocyte, cytokine and autoantibody
networks across subphenotypes will guide stratification into minimalistic targeted regimens.
Leveraging genetic risk loci may preemptively interrupt disease cascades before irreversible
injury occurs. Overall, elucidating CSS's molecular underpinnings holds promise refining
precision management for an enigmatic though medically actionable syndrome.
As a rare multi-system vasculitic disorder associated with asthma and peripheral blood
eosinophilia, Churg-Strauss syndrome (CSS) highlights complex immune interactions
underlying chronic inflammation. Named for the pathologists describing its pulmonary
pathology in 1951, CSS predominantly afflicts the lungs, heart and nerves yet remains poorly
understood. While glucocorticoids induce remission, relapses demand judicious
immunosuppression. Molecular mechanisms continue elucidating pathogenic eosinophilia,
elucidating new therapeutic angles. This review describes CSS clinical spectrum,
histopathology, criteria for diagnosis and the evolving immunological backdrop against
which treatment continues optimization.
Clinical Presentations
CSS involves multiple organs through variable symptoms constituting four distinct phases:
- Prodromal Asthma: Persistent allergic rhinitis, asthma diagnosed ≥6
months prior onset dominates here.
- Eosinophilic Phase: Marked blood/tissue eosinophilia with pulmonary infiltrates and
cardiomyopathy potentially lethal if untreated.
- Vasculitic Phase: Mononeuritis multiplex, alveolar hemorrhage, glomerulonephritis from
small/medium vessel necrotizing angiitis arise.
- Refractory Phase: Rare untreated patients display granulomatous involvement of lungs,
heart, kidney with fibrosis complicating long-term outcomes.
Manifestations arise from circulating and tissue-infiltrating eosinophils causing endothelial
damage and ischemic tissue injury vis complement activation, releasing toxic granule
proteins and reactive oxygen species.
Histopathology
Biopsies variably display:
- Pulmonary: Eosinophilic pneumonia with interstitial/intra-alveolar infiltrates and
eosinophilic abscesses.
- Peripheral Nerve: Mononuclear perineuritis prominently involving vasculitic nerves.
- Myocardium: Epicardial, endocardial eosinophilic infiltrates with fibrotic remodeling of
myocardial architecture over time.
- Kidney: Focal necrotizing glomerulonephritis with extracapillary proliferation and crescent
formation.
Eosinophil-rich inflammatory foci intermixed with necrotizing vascular lesions propagate
multi-organ injury here.
Diagnostic Criteria
American College of Rheumatology consensus diagnosis requires four or more items
including:
- Asthma
- Eosinophilia >10% on differential
- Mononeuropathy (including multiplex) or polyneuropathy
- Non-fixed pulmonary infiltrates on radiography
- Paranasal sinus abnormality
- Biopsy demonstrating blood vessel eosinophilic infiltrates
Presence of at least two items confers 90% specificity while histology most reliably
distinguishes from hypereosinophilic syndromes lacking angiitis.
Immunopathogenesis
Though etiology remains unclear, leading hypotheses implicate:
- Genetic predisposition conveyed by HLA-DRB1*04 alleles and dysregulated T cell subsets
propagating Type 2 T-helper cell responses.
- Autoimmunity directed against self-antigens expressed on lung basement membranes
potentiating pathological eosinophilia.
- Aberrant signalling through interleukin-5, eotaxin and other eosinophilopoietic chemokines
elevating numbers/activation states.
- Eosinophil adhesion/recruitment factors directing migratory patterns towards tissues
releasing damage mediators.
- Complement activation downstream releasing C5a anaphylatoxin promoting angiogenesis
and endothelial damage.
Unraveling these pathogenic pathways informs targeted therapeutic approaches.
Treatment Strategies
In CSS, immunosuppression aims at disease control in remission induction then maintenance
phases:
- Induction reverses clinical manifestations/eosinophilia with pulsed intravenous
methylprednisolone then oral prednisone over months.
- Cytotoxic immunoablation utilizes cyclophosphamide pulsing to accelerate remission
attainment alongside glucocorticoids.
- Maintenance employs less toxic therapies minimizing relapses/complications including
azathioprine, methotrexate or mycophenolate mofetil.
- Refractory/relapsing disease warrants anti-IL5 monoclonal antibodies mepolizumab or
benralizumab depleting pathogenic eosinophils directly.
- Plasmapheresis rapidly clears autoantibodies/complement components during severe
alveolar hemorrhage or myocarditis crises.
Newer targeted molecules inhibiting specific T-cell subsets, chemokines or complement
pathways present promising adjuncts.
Challenges and Unresolved Questions
With survivorship improved, priorities emerge addressing:
- Defining predictive biomarkers guiding individualized induction/maintenance durations
limiting cumulative toxicity.
- Addressing cardiac remodeling preventing dilated cardiomyopathy contributing to long-
term mortality.
- Optimizing neuroprotective strategies halting small fiber neuropathy progression impairing
quality of life.
- Clarifying whether hypereosinophilia denotes pre-staging or phenotypic variant from
angiitis-associated CSS.
- Identifying environmental/infectious triggers breaking tolerance specifically in atopic
individuals.
- Determining whether antigen-specific immune deviations perpetuate relapsing cycles
amenable to tolerance induction.
Ongoing mechanistic studies addressing these uncertainties will translate to personalized
precision therapy optimizing outcomes.
Concluding Remarks
As an organ-damaging eosinophil-associated vasculitis, CSS showcases immunology's
complexity regulating inflammation. Considerable progress defined diagnostic criteria,
induced safer remissions yet preventing relapses/complications demands further tailored
therapies. Multi-omic studies discerning pathogenic leukocyte, cytokine and autoantibody
networks across subphenotypes will guide stratification into minimalistic targeted regimens.
Leveraging genetic risk loci may preemptively interrupt disease cascades before irreversible
injury occurs. Overall, elucidating CSS's molecular underpinnings holds promise refining
precision management for an enigmatic though medically actionable syndrome.
As a rare multi-system vasculitic disorder associated with asthma and peripheral blood
eosinophilia, Churg-Strauss syndrome (CSS) highlights complex immune interactions
underlying chronic inflammation. Named for the pathologists describing its pulmonary
pathology in 1951, CSS predominantly afflicts the lungs, heart and nerves yet remains poorly
understood. While glucocorticoids induce remission, relapses demand judicious
immunosuppression. Molecular mechanisms continue elucidating pathogenic eosinophilia,
elucidating new therapeutic angles. This review describes CSS clinical spectrum,
histopathology, criteria for diagnosis and the evolving immunological backdrop against
which treatment continues optimization.
Clinical Presentations
CSS involves multiple organs through variable symptoms constituting four distinct phases:
- Prodromal Asthma: Persistent allergic rhinitis, asthma diagnosed ≥6
months prior onset dominates here.
- Eosinophilic Phase: Marked blood/tissue eosinophilia with pulmonary infiltrates and
cardiomyopathy potentially lethal if untreated.
- Vasculitic Phase: Mononeuritis multiplex, alveolar hemorrhage, glomerulonephritis from
small/medium vessel necrotizing angiitis arise.
- Refractory Phase: Rare untreated patients display granulomatous involvement of lungs,
heart, kidney with fibrosis complicating long-term outcomes.
Manifestations arise from circulating and tissue-infiltrating eosinophils causing endothelial
damage and ischemic tissue injury vis complement activation, releasing toxic granule
proteins and reactive oxygen species.
Histopathology
Biopsies variably display:
- Pulmonary: Eosinophilic pneumonia with interstitial/intra-alveolar infiltrates and
eosinophilic abscesses.
- Peripheral Nerve: Mononuclear perineuritis prominently involving vasculitic nerves.
- Myocardium: Epicardial, endocardial eosinophilic infiltrates with fibrotic remodeling of
myocardial architecture over time.
- Kidney: Focal necrotizing glomerulonephritis with extracapillary proliferation and crescent
formation.
Eosinophil-rich inflammatory foci intermixed with necrotizing vascular lesions propagate
multi-organ injury here.
Diagnostic Criteria
American College of Rheumatology consensus diagnosis requires four or more items
including:
- Asthma
- Eosinophilia >10% on differential
- Mononeuropathy (including multiplex) or polyneuropathy
- Non-fixed pulmonary infiltrates on radiography
- Paranasal sinus abnormality
- Biopsy demonstrating blood vessel eosinophilic infiltrates
Presence of at least two items confers 90% specificity while histology most reliably
distinguishes from hypereosinophilic syndromes lacking angiitis.
Immunopathogenesis
Though etiology remains unclear, leading hypotheses implicate:
- Genetic predisposition conveyed by HLA-DRB1*04 alleles and dysregulated T cell subsets
propagating Type 2 T-helper cell responses.
- Autoimmunity directed against self-antigens expressed on lung basement membranes
potentiating pathological eosinophilia.
- Aberrant signalling through interleukin-5, eotaxin and other eosinophilopoietic chemokines
elevating numbers/activation states.
- Eosinophil adhesion/recruitment factors directing migratory patterns towards tissues
releasing damage mediators.
- Complement activation downstream releasing C5a anaphylatoxin promoting angiogenesis
and endothelial damage.
Unraveling these pathogenic pathways informs targeted therapeutic approaches.
Treatment Strategies
In CSS, immunosuppression aims at disease control in remission induction then maintenance
phases:
- Induction reverses clinical manifestations/eosinophilia with pulsed intravenous
methylprednisolone then oral prednisone over months.
- Cytotoxic immunoablation utilizes cyclophosphamide pulsing to accelerate remission
attainment alongside glucocorticoids.
- Maintenance employs less toxic therapies minimizing relapses/complications including
azathioprine, methotrexate or mycophenolate mofetil.
- Refractory/relapsing disease warrants anti-IL5 monoclonal antibodies mepolizumab or
benralizumab depleting pathogenic eosinophils directly.
- Plasmapheresis rapidly clears autoantibodies/complement components during severe
alveolar hemorrhage or myocarditis crises.
Newer targeted molecules inhibiting specific T-cell subsets, chemokines or complement
pathways present promising adjuncts.
Challenges and Unresolved Questions
With survivorship improved, priorities emerge addressing:
- Defining predictive biomarkers guiding individualized induction/maintenance durations
limiting cumulative toxicity.
- Addressing cardiac remodeling preventing dilated cardiomyopathy contributing to long-
term mortality.
- Optimizing neuroprotective strategies halting small fiber neuropathy progression impairing
quality of life.
- Clarifying whether hypereosinophilia denotes pre-staging or phenotypic variant from
angiitis-associated CSS.
- Identifying environmental/infectious triggers breaking tolerance specifically in atopic
individuals.
- Determining whether antigen-specific immune deviations perpetuate relapsing cycles
amenable to tolerance induction.
Ongoing mechanistic studies addressing these uncertainties will translate to personalized
precision therapy optimizing outcomes.
Concluding Remarks
As an organ-damaging eosinophil-associated vasculitis, CSS showcases immunology's
complexity regulating inflammation. Considerable progress defined diagnostic criteria,
induced safer remissions yet preventing relapses/complications demands further tailored
therapies. Multi-omic studies discerning pathogenic leukocyte, cytokine and autoantibody
networks across subphenotypes will guide stratification into minimalistic targeted regimens.
Leveraging genetic risk loci may preemptively interrupt disease cascades before irreversible
injury occurs. Overall, elucidating CSS's molecular underpinnings holds promise refining
precision management for an enigmatic though medically actionable syndrome.
As a rare multi-system vasculitic disorder associated with asthma and peripheral blood
eosinophilia, Churg-Strauss syndrome (CSS) highlights complex immune interactions
underlying chronic inflammation. Named for the pathologists describing its pulmonary
pathology in 1951, CSS predominantly afflicts the lungs, heart and nerves yet remains poorly
understood. While glucocorticoids induce remission, relapses demand judicious
immunosuppression. Molecular mechanisms continue elucidating pathogenic eosinophilia,
elucidating new therapeutic angles. This review describes CSS clinical spectrum,
histopathology, criteria for diagnosis and the evolving immunological backdrop against
which treatment continues optimization.
Clinical Presentations
CSS involves multiple organs through variable symptoms constituting four distinct phases:
- Prodromal Asthma: Persistent allergic rhinitis, asthma diagnosed ≥6
months prior onset dominates here.
- Eosinophilic Phase: Marked blood/tissue eosinophilia with pulmonary infiltrates and
cardiomyopathy potentially lethal if untreated.
- Vasculitic Phase: Mononeuritis multiplex, alveolar hemorrhage, glomerulonephritis from
small/medium vessel necrotizing angiitis arise.
- Refractory Phase: Rare untreated patients display granulomatous involvement of lungs,
heart, kidney with fibrosis complicating long-term outcomes.
Manifestations arise from circulating and tissue-infiltrating eosinophils causing endothelial
damage and ischemic tissue injury vis complement activation, releasing toxic granule
proteins and reactive oxygen species.
Histopathology
Biopsies variably display:
- Pulmonary: Eosinophilic pneumonia with interstitial/intra-alveolar infiltrates and
eosinophilic abscesses.
- Peripheral Nerve: Mononuclear perineuritis prominently involving vasculitic nerves.
- Myocardium: Epicardial, endocardial eosinophilic infiltrates with fibrotic remodeling of
myocardial architecture over time.
- Kidney: Focal necrotizing glomerulonephritis with extracapillary proliferation and crescent
formation.
Eosinophil-rich inflammatory foci intermixed with necrotizing vascular lesions propagate
multi-organ injury here.
Diagnostic Criteria
American College of Rheumatology consensus diagnosis requires four or more items
including:
- Asthma
- Eosinophilia >10% on differential
- Mononeuropathy (including multiplex) or polyneuropathy
- Non-fixed pulmonary infiltrates on radiography
- Paranasal sinus abnormality
- Biopsy demonstrating blood vessel eosinophilic infiltrates
Presence of at least two items confers 90% specificity while histology most reliably
distinguishes from hypereosinophilic syndromes lacking angiitis.
Immunopathogenesis
Though etiology remains unclear, leading hypotheses implicate:
- Genetic predisposition conveyed by HLA-DRB1*04 alleles and dysregulated T cell subsets
propagating Type 2 T-helper cell responses.
- Autoimmunity directed against self-antigens expressed on lung basement membranes
potentiating pathological eosinophilia.
- Aberrant signalling through interleukin-5, eotaxin and other eosinophilopoietic chemokines
elevating numbers/activation states.
- Eosinophil adhesion/recruitment factors directing migratory patterns towards tissues
releasing damage mediators.
- Complement activation downstream releasing C5a anaphylatoxin promoting angiogenesis
and endothelial damage.
Unraveling these pathogenic pathways informs targeted therapeutic approaches.
Treatment Strategies
In CSS, immunosuppression aims at disease control in remission induction then maintenance
phases:
- Induction reverses clinical manifestations/eosinophilia with pulsed intravenous
methylprednisolone then oral prednisone over months.
- Cytotoxic immunoablation utilizes cyclophosphamide pulsing to accelerate remission
attainment alongside glucocorticoids.
- Maintenance employs less toxic therapies minimizing relapses/complications including
azathioprine, methotrexate or mycophenolate mofetil.
- Refractory/relapsing disease warrants anti-IL5 monoclonal antibodies mepolizumab or
benralizumab depleting pathogenic eosinophils directly.
- Plasmapheresis rapidly clears autoantibodies/complement components during severe
alveolar hemorrhage or myocarditis crises.
Newer targeted molecules inhibiting specific T-cell subsets, chemokines or complement
pathways present promising adjuncts.
Challenges and Unresolved Questions
With survivorship improved, priorities emerge addressing:
- Defining predictive biomarkers guiding individualized induction/maintenance durations
limiting cumulative toxicity.
- Addressing cardiac remodeling preventing dilated cardiomyopathy contributing to long-
term mortality.
- Optimizing neuroprotective strategies halting small fiber neuropathy progression impairing
quality of life.
- Clarifying whether hypereosinophilia denotes pre-staging or phenotypic variant from
angiitis-associated CSS.
- Identifying environmental/infectious triggers breaking tolerance specifically in atopic
individuals.
- Determining whether antigen-specific immune deviations perpetuate relapsing cycles
amenable to tolerance induction.
Ongoing mechanistic studies addressing these uncertainties will translate to personalized
precision therapy optimizing outcomes.
Concluding Remarks
As an organ-damaging eosinophil-associated vasculitis, CSS showcases immunology's
complexity regulating inflammation. Considerable progress defined diagnostic criteria,
induced safer remissions yet preventing relapses/complications demands further tailored
therapies. Multi-omic studies discerning pathogenic leukocyte, cytokine and autoantibody
networks across subphenotypes will guide stratification into minimalistic targeted regimens.
Leveraging genetic risk loci may preemptively interrupt disease cascades before irreversible
injury occurs. Overall, elucidating CSS's molecular underpinnings holds promise refining
precision management for an enigmatic though medically actionable syndrome.
As a rare multi-system vasculitic disorder associated with asthma and peripheral blood
eosinophilia, Churg-Strauss syndrome (CSS) highlights complex immune interactions
underlying chronic inflammation. Named for the pathologists describing its pulmonary
pathology in 1951, CSS predominantly afflicts the lungs, heart and nerves yet remains poorly
understood. While glucocorticoids induce remission, relapses demand judicious
immunosuppression. Molecular mechanisms continue elucidating pathogenic eosinophilia,
elucidating new therapeutic angles. This review describes CSS clinical spectrum,
histopathology, criteria for diagnosis and the evolving immunological backdrop against
which treatment continues optimization.
Clinical Presentations
CSS involves multiple organs through variable symptoms constituting four distinct phases:
- Prodromal Asthma: Persistent allergic rhinitis, asthma diagnosed ≥6
months prior onset dominates here.
- Eosinophilic Phase: Marked blood/tissue eosinophilia with pulmonary infiltrates and
cardiomyopathy potentially lethal if untreated.
- Vasculitic Phase: Mononeuritis multiplex, alveolar hemorrhage, glomerulonephritis from
small/medium vessel necrotizing angiitis arise.
- Refractory Phase: Rare untreated patients display granulomatous involvement of lungs,
heart, kidney with fibrosis complicating long-term outcomes.
Manifestations arise from circulating and tissue-infiltrating eosinophils causing endothelial
damage and ischemic tissue injury vis complement activation, releasing toxic granule
proteins and reactive oxygen species.
Histopathology
Biopsies variably display:
- Pulmonary: Eosinophilic pneumonia with interstitial/intra-alveolar infiltrates and
eosinophilic abscesses.
- Peripheral Nerve: Mononuclear perineuritis prominently involving vasculitic nerves.
- Myocardium: Epicardial, endocardial eosinophilic infiltrates with fibrotic remodeling of
myocardial architecture over time.
- Kidney: Focal necrotizing glomerulonephritis with extracapillary proliferation and crescent
formation.
Eosinophil-rich inflammatory foci intermixed with necrotizing vascular lesions propagate
multi-organ injury here.
Diagnostic Criteria
American College of Rheumatology consensus diagnosis requires four or more items
including:
- Asthma
- Eosinophilia >10% on differential
- Mononeuropathy (including multiplex) or polyneuropathy
- Non-fixed pulmonary infiltrates on radiography
- Paranasal sinus abnormality
- Biopsy demonstrating blood vessel eosinophilic infiltrates
Presence of at least two items confers 90% specificity while histology most reliably
distinguishes from hypereosinophilic syndromes lacking angiitis.
Immunopathogenesis
Though etiology remains unclear, leading hypotheses implicate:
- Genetic predisposition conveyed by HLA-DRB1*04 alleles and dysregulated T cell subsets
propagating Type 2 T-helper cell responses.
- Autoimmunity directed against self-antigens expressed on lung basement membranes
potentiating pathological eosinophilia.
- Aberrant signalling through interleukin-5, eotaxin and other eosinophilopoietic chemokines
elevating numbers/activation states.
- Eosinophil adhesion/recruitment factors directing migratory patterns towards tissues
releasing damage mediators.
- Complement activation downstream releasing C5a anaphylatoxin promoting angiogenesis
and endothelial damage.
Unraveling these pathogenic pathways informs targeted therapeutic approaches.
Treatment Strategies
In CSS, immunosuppression aims at disease control in remission induction then maintenance
phases:
- Induction reverses clinical manifestations/eosinophilia with pulsed intravenous
methylprednisolone then oral prednisone over months.
- Cytotoxic immunoablation utilizes cyclophosphamide pulsing to accelerate remission
attainment alongside glucocorticoids.
- Maintenance employs less toxic therapies minimizing relapses/complications including
azathioprine, methotrexate or mycophenolate mofetil.
- Refractory/relapsing disease warrants anti-IL5 monoclonal antibodies mepolizumab or
benralizumab depleting pathogenic eosinophils directly.
- Plasmapheresis rapidly clears autoantibodies/complement components during severe
alveolar hemorrhage or myocarditis crises.
Newer targeted molecules inhibiting specific T-cell subsets, chemokines or complement
pathways present promising adjuncts.
Challenges and Unresolved Questions
With survivorship improved, priorities emerge addressing:
- Defining predictive biomarkers guiding individualized induction/maintenance durations
limiting cumulative toxicity.
- Addressing cardiac remodeling preventing dilated cardiomyopathy contributing to long-
term mortality.
- Optimizing neuroprotective strategies halting small fiber neuropathy progression impairing
quality of life.
- Clarifying whether hypereosinophilia denotes pre-staging or phenotypic variant from
angiitis-associated CSS.
- Identifying environmental/infectious triggers breaking tolerance specifically in atopic
individuals.
- Determining whether antigen-specific immune deviations perpetuate relapsing cycles
amenable to tolerance induction.
Ongoing mechanistic studies addressing these uncertainties will translate to personalized
precision therapy optimizing outcomes.
Concluding Remarks
As an organ-damaging eosinophil-associated vasculitis, CSS showcases immunology's
complexity regulating inflammation. Considerable progress defined diagnostic criteria,
induced safer remissions yet preventing relapses/complications demands further tailored
therapies. Multi-omic studies discerning pathogenic leukocyte, cytokine and autoantibody
networks across subphenotypes will guide stratification into minimalistic targeted regimens.
Leveraging genetic risk loci may preemptively interrupt disease cascades before irreversible
injury occurs. Overall, elucidating CSS's molecular underpinnings holds promise refining
precision management for an enigmatic though medically actionable syndrome.
As a rare multi-system vasculitic disorder associated with asthma and peripheral blood
eosinophilia, Churg-Strauss syndrome (CSS) highlights complex immune interactions
underlying chronic inflammation. Named for the pathologists describing its pulmonary
pathology in 1951, CSS predominantly afflicts the lungs, heart and nerves yet remains poorly
understood. While glucocorticoids induce remission, relapses demand judicious
immunosuppression. Molecular mechanisms continue elucidating pathogenic eosinophilia,
elucidating new therapeutic angles. This review describes CSS clinical spectrum,
histopathology, criteria for diagnosis and the evolving immunological backdrop against
which treatment continues optimization.
Clinical Presentations
CSS involves multiple organs through variable symptoms constituting four distinct phases:
- Prodromal Asthma: Persistent allergic rhinitis, asthma diagnosed ≥6
months prior onset dominates here.
- Eosinophilic Phase: Marked blood/tissue eosinophilia with pulmonary infiltrates and
cardiomyopathy potentially lethal if untreated.
- Vasculitic Phase: Mononeuritis multiplex, alveolar hemorrhage, glomerulonephritis from
small/medium vessel necrotizing angiitis arise.
- Refractory Phase: Rare untreated patients display granulomatous involvement of lungs,
heart, kidney with fibrosis complicating long-term outcomes.
Manifestations arise from circulating and tissue-infiltrating eosinophils causing endothelial
damage and ischemic tissue injury vis complement activation, releasing toxic granule
proteins and reactive oxygen species.
Histopathology
Biopsies variably display:
- Pulmonary: Eosinophilic pneumonia with interstitial/intra-alveolar infiltrates and
eosinophilic abscesses.
- Peripheral Nerve: Mononuclear perineuritis prominently involving vasculitic nerves.
- Myocardium: Epicardial, endocardial eosinophilic infiltrates with fibrotic remodeling of
myocardial architecture over time.
- Kidney: Focal necrotizing glomerulonephritis with extracapillary proliferation and crescent
formation.
Eosinophil-rich inflammatory foci intermixed with necrotizing vascular lesions propagate
multi-organ injury here.
Diagnostic Criteria
American College of Rheumatology consensus diagnosis requires four or more items
including:
- Asthma
- Eosinophilia >10% on differential
- Mononeuropathy (including multiplex) or polyneuropathy
- Non-fixed pulmonary infiltrates on radiography
- Paranasal sinus abnormality
- Biopsy demonstrating blood vessel eosinophilic infiltrates
Presence of at least two items confers 90% specificity while histology most reliably
distinguishes from hypereosinophilic syndromes lacking angiitis.
Immunopathogenesis
Though etiology remains unclear, leading hypotheses implicate:
- Genetic predisposition conveyed by HLA-DRB1*04 alleles and dysregulated T cell subsets
propagating Type 2 T-helper cell responses.
- Autoimmunity directed against self-antigens expressed on lung basement membranes
potentiating pathological eosinophilia.
- Aberrant signalling through interleukin-5, eotaxin and other eosinophilopoietic chemokines
elevating numbers/activation states.
- Eosinophil adhesion/recruitment factors directing migratory patterns towards tissues
releasing damage mediators.
- Complement activation downstream releasing C5a anaphylatoxin promoting angiogenesis
and endothelial damage.
Unraveling these pathogenic pathways informs targeted therapeutic approaches.
Treatment Strategies
In CSS, immunosuppression aims at disease control in remission induction then maintenance
phases:
- Induction reverses clinical manifestations/eosinophilia with pulsed intravenous
methylprednisolone then oral prednisone over months.
- Cytotoxic immunoablation utilizes cyclophosphamide pulsing to accelerate remission
attainment alongside glucocorticoids.
- Maintenance employs less toxic therapies minimizing relapses/complications including
azathioprine, methotrexate or mycophenolate mofetil.
- Refractory/relapsing disease warrants anti-IL5 monoclonal antibodies mepolizumab or
benralizumab depleting pathogenic eosinophils directly.
- Plasmapheresis rapidly clears autoantibodies/complement components during severe
alveolar hemorrhage or myocarditis crises.
Newer targeted molecules inhibiting specific T-cell subsets, chemokines or complement
pathways present promising adjuncts.
Challenges and Unresolved Questions
With survivorship improved, priorities emerge addressing:
- Defining predictive biomarkers guiding individualized induction/maintenance durations
limiting cumulative toxicity.
- Addressing cardiac remodeling preventing dilated cardiomyopathy contributing to long-
term mortality.
- Optimizing neuroprotective strategies halting small fiber neuropathy progression impairing
quality of life.
- Clarifying whether hypereosinophilia denotes pre-staging or phenotypic variant from
angiitis-associated CSS.
- Identifying environmental/infectious triggers breaking tolerance specifically in atopic
individuals.
- Determining whether antigen-specific immune deviations perpetuate relapsing cycles
amenable to tolerance induction.
Ongoing mechanistic studies addressing these uncertainties will translate to personalized
precision therapy optimizing outcomes.
Concluding Remarks
As an organ-damaging eosinophil-associated vasculitis, CSS showcases immunology's
complexity regulating inflammation. Considerable progress defined diagnostic criteria,
induced safer remissions yet preventing relapses/complications demands further tailored
therapies. Multi-omic studies discerning pathogenic leukocyte, cytokine and autoantibody
networks across subphenotypes will guide stratification into minimalistic targeted regimens.
Leveraging genetic risk loci may preemptively interrupt disease cascades before irreversible
injury occurs. Overall, elucidating CSS's molecular underpinnings holds promise refining
precision management for an enigmatic though medically actionable syndrome.
